Need-adapted HCV-treatment setting for injection drug users

The Lancet

Volumn 373, Issue 9681, 2009, Pages 2090-2091

  Reimer, Jens ^a   Haasen, Christian ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLISM; ANTIVIRAL THERAPY; ARTICLE; COMORBIDITY; DRUG USE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBSTANCE ABUSE; TREATMENT INDICATION; VIROLOGY;

EID: 67149143393     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60347-0     Document Type: Note

References (13)

1. Stoové M.A., Gifford S.M., and Dore G.J. The impact of injecting drug use status on hepatitis-C-related referral and treatment. Drug Alcohol Depend 77 (2005) 81-86
2. Wilkinson M., Crawford V., Tippet A., et al. Community based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite on-going drug use (HCV in drug users). Aliment Pharmacol Ther (2008) 10.1111/j.1365-2036.2008.03834.x published online Aug 26.
3. Jack K., Willot S., Manners J., Varnam M.A., and Thomson B.J. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther (2008) 10.1111/j.1365-2036.2008.03872.x published online Oct 11.
4. Neuman M.G., Brenner D.A., Rehermann B., et al. Hepatitis C and alcohol liver disease: cytokines. Alcohol Clin Exp Res 25 suppl 1 (2003) 251S-253S
5. Weber R., Sabin C.A., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 (2006) 1632-1641
6. Anand B.S., Currie S., Dieperink E., et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 130 (2006) 1607-1616
7. Wong J.B. Hepatitis C. Cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 24 (2006) 661-672
8. Wright T.L. Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatol Res 37 suppl 2 (2007) S294-S298
9. Mehta S.H., Genberg B.L., Astemborski J., et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 33 (2008) 126-133
10. Edlin B.R., Kresina T.F., Raymond D.B., et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 40 suppl 5 (2005) S276-S285
11. Laine C., Hauck W.W., Gourevitch M.N., et al. Regular out-patient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 285 (2001) 2355-2362
12. Paterson B.L., Backmund M., Hirsch G., and Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 18 (2007) 364-373
13. Wright C., Burns T., James P., et al. Assertive outreach teams in London: models of operation. Pan-London Assertive Outreach Study, part 1. Br J Psychiatry 183 (2003) 132-138